Our Unique Consortium

Sydney Catalyst is a multi-disciplinary, multi-institutional endeavour established with core funding from the Cancer Institute NSW and based at the University of Sydney.

Read more

Event
Implementation and Dissemination of Evidence for Adoption and Application (IDEA)  Concept Development Workshop

Workshops and Masterclasses

Implementation and Dissemination of Evidence for Adoption and Application (IDEA) Concept Development Workshop

This interactive half day workshop will examine the fundamental concepts in implementation science to assist mid-career clinicians and researchers from diverse cancer disciplines to design and con...

Read more
Event
EDS: Primary Liver Cancer - Hepatology Meets Oncology

Education Dinner Series

EDS: Primary Liver Cancer - Hepatology Meets Oncology

Overview Primary liver cancer has become one of the top ten causes of cancer death in Australia and it is increasing, with almost 1,400 new diagnoses each year in Australia. The most common...

Read more
Event
Clinical Dilemma & Concept Development Workshop

Workshops and Masterclasses

Clinical Dilemma & Concept Development Workshop

What? Are you a clinician who has noticed a clinical problem in your daily practice? Is there an issue you face in your clinical work that presents a challenge? Do patients or caregivers often dr...

Read more
News
Sydney Catalyst September 2017 Newsletter

Newsletters

Sydney Catalyst September 2017 Newsletter

Read about members in the news, upcoming events, awards, opportunities and more. Happy reading! Read More

Read more
Research
Helen McGuire: Development of a novel test to predict clinical response to checkpoint therapy in lung cancer and mesothelioma

T1 | Flagship 2 Pilot and Seed

Helen McGuire: Development of a novel test to predict clinical response to checkpoint therapy in lung cancer and mesothelioma

Immune checkpoint inhibitor therapy has provided new hope to cancer patients whose tumours have resisted conventional therapy. One of the most recent success stories has been effective treatment o...

Read more
ImmunotherapyNew therapies and diagnosticsLung cancerMesothelioma
News
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

News Articles

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

Published online 1 September 2017 in the Lancet,  were results of a first-in-man study of TargomiRs. The study showed that a dose of 5 × 10⁹ TargomiRs per week was well tolerated and was...

Read more
News
Early Career Researcher, Breast Cancer Research Program

News Articles

Early Career Researcher, Breast Cancer Research Program

A research role has become available, within the NBCF-funded Breast Cancer Research Program (BCRP), for a very early post-doctoral researcher interested in developing skills and knowledge in breas...

Read more
Research
David Thomas & Team: Molecular Screening and Therapeutics Program (MOST)

T1,T2 | Sydney Catalyst Supported

David Thomas & Team: Molecular Screening and Therapeutics Program (MOST)

The rapid advance in genomic technologies presents the unprecedented opportunity to molecularly phenotype cancers and link genetic information to therapeutic opportunities for individual patients....

Read more
Genetics/genomicsPersonalised medicineNew therapies and diagnostics
Research
Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)

T1,T2,T3 | Flagship 1 EnRICH

Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)

The program will develop infrastructure to support translational cancer research, initially with a focus on lung cancer. Specifically, EnRICH will assemble a prospective cohort of 1000 newly d...

Read more
Epidemiology and health services researchImplementation researchKnowledge translationLung cancer